Exchange: NASDAQ·Updated 09:51 PM EDT

TWST News

News
all
press releases
TWST Stock Hits Multi-Year High, But ‘Pharma Bro’ Martin Shkreli Calls Twist A Short
Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.
Stocktwits
More News
HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
Haemonetics and Twist Bioscience stocks surged to more than five-year highs on Thursday, as fresh growth opportunities drew cheer from Wall Street.
Stocktwits
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for...
Business Wire
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 PR Newswire AUSTIN, Texas, Sept. 3, 2026 AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt...
PR Newswire
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven protein design campaign. The bullish momentum overshadows a critical short report published on X by activist short-seller Scorpion Capital.read more...
Benzinga
Twist Bioscience Stock Hits 52-Week High - Here's Why
Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins. Get the full market update.read more...
Benzinga
‘Pharma Bro’ Martin Shkreli Slams Anthropic’s Claude Drug-Discovery Claims: ‘This Is Not Impressive Work’
Claude-designed proteins successfully bound to 14 of 15 targets in independent testing by Adaptyv Bio and Twist Bioscience.
Stocktwits
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold...
Business Wire
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist Bioscience Corporation (Nasdaq: TWST) (Twist), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up...
Business Wire

Advertisement|Remove ads.